3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
11
Sarcoma
4
Gynecologic
4
Genitourinary
3
Gastrointestinal
3
Breast
3
Thoracic
2
Dermatologic
2
NET
1
Lymphoid
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
34
Pheochromocytoma
4
Paraganglioma
4
Carcinoma, Neuroendocrine
4
Sarcoma
3
Pancreatic Neoplasms
3
Neoplasms
3
Meningioma
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Carcinoid Tumor
3
Adenoma, Islet Cell
3
Thyroid Neoplasms
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neuroblastoma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Melanoma
2
Medulloblastoma
2
Liver Neoplasms
2
Insulinoma
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Gastro-enteropancreatic neuroendocrine tumor
2
Digestive System Neoplasms
2
Colonic Neoplasms
2
Interventions
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
NET
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA